Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia.
Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia.
复制标题
DOI：
10.4088/jcp.v65n0710
复制
发表时间：
2004-07
期刊：
影响因子：
--
通讯作者：
X. Zhang;D. Zhou;L. Cao;P. Zhang;G. Wu;Y. Shen
中科院分区：
文献类型：
--
作者：
X. Zhang;D. Zhou;L. Cao;P. Zhang;G. Wu;Y. Shen
许多研究表明免疫细胞因子可能参与精神分裂症的病理生理过程。最近，有报道称，典型和非典型抗精神病药物可能会影响细胞因子或细胞因子受体的水平。本研究旨在比较典型和非典型抗精神病药物对精神分裂症患者血清白细胞介素-2（IL-2）、白细胞介素-6（IL-6）和白细胞介素-8（IL-8）的影响，并探讨细胞因子变化与精神分裂症治疗结局的关系。方法1996年4月至1997年8月，将78例诊断为慢性精神分裂症（DSM-Ⅲ-R）的住院患者随机分为两组，分别给予利培酮6 mg/d和氟哌啶醇20 mg/d治疗12周。采用阳性和阴性症状量表测定临床疗效。采用放射免疫分析法测定患者血清IL-2水平，采用酶联免疫吸附法测定患者血清IL-6和IL-8水平。结果利培酮和氟哌啶醇均能降低精神分裂症患者血清IL-2水平，但利培酮和氟哌啶醇对血清IL-2水平的降低无显著性差异。利培酮和氟哌啶醇对精神分裂症患者血清IL-6和IL-8浓度升高无明显影响。观察了基线时血清IL-2或IL-8浓度与治疗结局之间的相关性，表明基线时血清IL-2或IL-8浓度低的患者治疗后改善更大，基线时血清IL-2或IL-8浓度较高的患者治疗后改善较少。结论：典型和非典型抗精神病药物至少可以部分地使精神分裂症患者的异常免疫改变正常化。基线时的某些免疫指标可能有助于预测精神分裂症患者的抗精神病药物反应。
BACKGROUND Many studies have indicated that immune cytokines may be involved in the pathophysiology of schizophrenia. Recently, there have been reports that typical and atypical antipsychotic drugs may influence the levels of cytokines or cytokine receptors. The aim of this study was to compare the effect of typical and atypical antipsychotic drugs on serum interleukin-2 (IL-2), interleukin-6 (IL-6), and interleukin-8 (IL-8) and to investigate the relationship between the changes in cytokines and the therapeutic outcome in schizophrenia. METHOD From April 1996 to August 1997, seventy-eight inpatients with a diagnosis of chronic schizophrenia (DSM-III-R) were randomly assigned to 12 weeks of treatment with 6 mg/day of risperidone or 20 mg/day of haloperidol. Clinical efficacy was determined using the Positive and Negative Syndrome Scale. Serum IL-2 was assayed by radioimmunometric assay, and serum IL-6 and IL-8 concentrations were measured by quantitative enzyme-linked immunosorbent assay in patients and 30 sex- and age-matched normal subjects. RESULTS Both risperidone and haloperidol reduced the elevated serum IL-2 concentrations in schizophrenia, and no significant difference was noted in the reduction of serum IL-2 concentrations between risperidone and haloperidol treatment. Neither risperidone nor haloperidol showed significant influence on the higher serum IL-6 or IL-8 concentrations in schizophrenia. Correlations between serum IL-2 or IL-8 concentrations at baseline and the therapeutic outcome were observed, demonstrating that patients presenting with low concentrations of serum IL-2 or IL-8 at baseline showed greater improvement and patients presenting with higher serum IL-2 or IL-8 concentrations at baseline showed less improvement after treatment. CONCLUSIONS Both typical and atypical anti-psychotic drugs may at least partially normalize abnormal immune alterations in schizophrenia. Some immune parameters at baseline may be useful for predicting the neuroleptic response of schizophrenic patients.